# Lorundrostat

Type: Product

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/lorundrostat
Canonical HTML page: https://getbiobrief.com/entity/lorundrostat

## Recent coverage (1 stories)

### Mineralys Therapeutics Advances Lorundrostat NDA Amid Q4 Earnings Beat
2026-03-12 23:33:25 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Mineralys Therapeutics (MLYS) reported a narrower-than-expected Q4 2025 loss and confirmed the FDA's acceptance of its New Drug Application for lorundrostat. The company is now pivoting toward commercial readiness for its lead hypertension candidate while maintaining a robust clinical pipeline in chronic kidney disease.
Full story: https://getbiobrief.com/story/mineralys-mlys-q4-2025-earnings-lorundrostat-nda

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.